LGD 4033 15 mg

LGD 4033 15 mg contains ligandrol, a SARM. It has no approved medical use. In non-medical bodybuilding contexts, it is commonly referenced for lean muscle gains and strength increases, though such use falls outside approved indications and carries health risks.

Ligandrol has a half-life commonly referenced as approximately 24–36 hours, supporting once-daily dosing. In non-medical contexts, it is typically referenced as being taken once daily, with doses ranging from 5–20 mg per day.

Yes. Ligandrol suppresses endogenous testosterone production, as demonstrated by dose-dependent suppression of total testosterone in clinical trials. In non-medical contexts, post-cycle therapy is commonly recommended. Agents such as Clomid or Nolvadex are commonly referenced for this purpose.

Ligandrol is a nonsteroidal SARM that binds the androgen receptor with high affinity and selectivity. It selectively activates androgenic signaling in muscle and bone, with less activity in prostate tissue compared to traditional androgens. Clinical trials demonstrated dose-dependent increases in lean body mass and suppression of testosterone, SHBG, and HDL cholesterol.

In clinical trials, ligandrol increased lean body mass over a 21-day treatment period at doses of 0.1–1.0 mg per day. In non-medical contexts at higher doses, users often report noticeable changes in muscle mass and strength within the first 4–8 weeks of use.

There is no universally "best" SARM. Ligandrol is distinguished by its high androgen receptor affinity and clinical trial data showing lean mass increases. Other SARMs such as MK 2866 or RAD 140 have different selectivity profiles and side effect characteristics. The appropriate choice, if any, depends on individual goals and risk tolerance.

Both are SARMs, but they have different receptor selectivity profiles and half-lives. Ligandrol is considered more potent for muscle mass gains, while MK 2866 (ostarine) is often described as milder and is commonly referenced for joint support and cutting phases. Ligandrol has been studied in clinical trials at doses up to 1.0 mg, while ostarine has been studied at higher doses.

Both are SARMs, but RAD 140 is generally considered more androgenic and is often referenced for strength and aggression, while ligandrol is referenced for lean mass gains. RAD 140 has not been studied in human clinical trials to the same extent as ligandrol.

Clinical trials used doses of 0.1–1.0 mg per day. In non-medical contexts, 15 mg per day is a commonly referenced dose, but it is substantially higher than clinical research doses and is not supported by safety data. LGD 4033 15 mg is labeled at 15 mg per tablet.

LGD 4033 15 mg is labeled at 15 mg of ligandrol per tablet. It is supplied in a 100-tablet package, giving 1,500 mg of total labeled ligandrol content.

Yes. Published laboratory reports for LGD 4033 15 mg are available. The most recent report dated April 18, 2025 measured the product at 15.66 mg per tablet, equivalent to 104.40% of its 15 mg label claim. Complete reports can be viewed in the Lab Reports tab.

No. Ligandrol is not approved by the FDA for human use and is classified as an unapproved new drug when sold for human consumption. It is prohibited by WADA at all times.